| Poorly Differentiated Thyroid Gland Carcinoma studied in …STUDIED_INderived19 of 19show fewer |
|---|
| → studied in | NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07485569Phase 1 · active not recruiting Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · condition mapped ALIAS · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02152995Phase 2 · active not recruiting Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04171622Phase 2 · active not recruiting Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914300Phase 2 · active not recruiting Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03181100Phase 2 · active not recruiting Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06959641Phase 2 · recruiting XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer · condition mapped CURATED_BROADER · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07068542NA · recruiting Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer · condition mapped ALIAS · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03449108Phase 2 · active not recruiting LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04759911Phase 2 · active not recruiting Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639191early Phase 1 · recruiting [177Lu]Lu-AKIR001 First-in-human Study · condition mapped ALIAS · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02973997Phase 2 · completed Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393690Phase 2 · completed Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04731740Phase 2 · withdrawn Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02041260Phase 2 · unknown A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting · condition mapped ALIAS · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03630120Phase 2 · terminated Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00654238Phase 2 · completed Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer · condition mapped CURATED_BROADER · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01811212Phase 2 · completed Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer · condition mapped ONTOLOGY_EXACT · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03387943Phase 2 · unknown PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma · condition mapped ALIAS · 19 trials mapped (11 active) | — | — | Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |